SYK Valuation Report 2026-07-31

Stryker Corporation is a diversified medical technology company focused on orthopedic and surgical solutions, generating revenue through implants, equipment, and increasingly, MedSurg/Neurotechnology disposables. Recent Q2 2026 results show 9% organic sales growth and adjusted EPS of $3.69, exceeding expectations, driven by a recovery from a prior cybersecurity incident and strong gross margins (66%). Strategic priorities include expanding robotic-assisted surgery with the new Mako RPS system. While valuation currently reflects investor caution (lower P/E ratio than historical average), projected 11.2% EPS CAGR through 2028 supports continued dividend growth. The company is navigating a stable but inflationary macroeconomic environment, prioritizing cost management and leveraging stable interest rates for investment. Recent capital allocation emphasizes acquisitions (like Inari Medical), operational restructuring, and shareholder returns. Risk factors include ongoing legal issues, supply chain vulnerabilities, and cybersecurity threats, requiring robust risk management. Long-term success hinges on sustaining growth, integrating acquisitions, and adapting to reimbursement changes, with a strategic shift towards the higher-growth Neurotechnology segment.